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Cancer is unique amongst human diseases in that its cel-
lular manifestations arise and evolve through the acquisi-
tion of somatic alterations in the genome. In particular, 
instability in the number and structure of chromosomes is 
a near-universal feature of the genomic alterations asso-
ciated with epithelial cancers, and is triggered by the inac-
tivation of tumour suppressor mechanisms that preserve 
chromosome integrity in normal cells. The nature of these 
mechanisms, and how their inactivation promotes carci-
nogenesis, remains enigmatic. I will review recent work 
from our laboratory on the tumour suppressor BRCA2 that 
addresses these issues, focusing on new insights into 
cancer pathogenesis and therapy that are emerging from 
improved understanding of the molecular basis of chro-
mosomal instability in BRCA2-deficient cancer cells. 
 
 
INTRODUCTION 
1 
It has been clear for many years that somatic alterations of the 
genome occur at a high frequency in the majority of cells iso-
lated from most common forms of cancer. Recent studies using 
next-generation sequencing (NGS) have provided a catalogue 
of such changes at much higher resolution than has previously 
been possible. Besides small sequence changes (such as point 
mutations, and small insertions or deletions of nucleotides), 
NGS studies highlight the abundance of chromosomal aberra-
tions in cancer genomes. These chromosomal aberrations in-
clude different forms of structural abnormalities, such as gross 
chromosomal rearrangements (eg., large insertions or deletions, 
rearrangement between chromosomes, chromosome fragmen-
tation etc) and regions of amplification, as well as numerical 
aberrations associated with the gain or loss of whole chromo-
somes (or aneuploidy). Neither the mechanisms underlying chro- 
mosomal instability in cancer cells, not its potential significance 
to carcinogenesis and cancer evolution, is well understood. 
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Inherited mutations affecting the BRCA2 tumour suppressor 
provide a powerful model in which to study these issues. 
BRCA2 was identified in the 1990s through the analysis of 
families at high risk from breast and ovarian cancer. It encodes 
a large protein, bearing little resemblance to molecules of 
known function, which is widely expressed in the dividing cells 
of many tissues, and localises to the cell nucleus. It has be-
come clear over the past decade that BRCA2 plays an essen-
tial role in preserving the structural and numerical stability of 
chromosomes during cell division. This review will focus on 
recent work from our laboratory that provides insights into the 
pathogenesis and treatment of epithelial cancers associated 
with BRCA2 mutations. 
 
GERMLINE BRCA2 MUTATIONS AND CANCER  
SUSCEPTIBILITY 
 
Germline mutations affecting one allele of BRCA2 were first 
shown to confer susceptibility to breast and ovarian cancers 
with a high penetrance, which, by the age of 70 years approa-
ches 40-50% for breast cancer, and 10-15% for ovarian. Indi-
viduals who carry BRCA2 mutations also have an increased 
risk of cancers of the male breast (~75-fold relative risk), pan-
creas (4-8-fold), prostate (2-4-fold) or other tissues (Breast Can- 
cer Linkage Consortium, 1999; Thompson and Easton, 2002). 
It has been proposed that germline heterozygosity for BRCA2 
mutations suffices for cancer predisposition, and there is evi-
dence that the second BRCA2 allele is inactivated by somatic 
alterations during tumour progression, consistent with the ex-
pectation for a classical ‘two hit’ tumour suppressor gene de-
scribed by Knudson. 
 
BRCA2 PERFORMS MULTIPLE CELLULAR  
FUNCTIONS IN TUMOUR SUPPRESSION 
 
A few years after the discovery of the human BRCA2 gene, we 
reported that cells carrying a genetically engineered truncation 
in murine BRCA2 spontaneously develop instability in chromo-
some structure and number during division (Fig. 1). These ab-
errations offer important clues to the cellular functions of BRCA2 
in tumour suppression. For instance, structural aberrations 
include many chromatid-type lesions, such as breaks that affect 
a single sister chromatid, as well as tri-radial and quadri-radial 
structures. Such aberrations are also diagnostic of Fanconi 
Anaemia, providing a first connection between this syndrome 
and cancers associated with BRCA2 deficiency (Patel et al., 
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1998). Similar abnormalities were afterwards shown to occur in 
murine cells lacking BRCA1 (Xu et al., 1999) and in cancer 
cells from BRCA mutation carriers (Gretarsdottir et al., 1998; 
Tirkkonen et al., 1997). 
Structural chromosomal aberrations following BRCA2 inacti-
vation are believed to arise from its role in DNA repair by homo-
logous recombination (HR). BRCA2 binds directly to the RAD51 
recombination enzyme, which has a catalytic activity central to 
HR. RAD51 coats single-stranded DNA substrates to form a 
helical nucleoprotein filament that invades and pairs with the 
homologous DNA duplex, initiating strand exchange between 
the paired DNA molecules (reviewed in West, 2003). There is 
compelling evidence that BRCA2 works directly to regulate the 
availability and activity of RAD51 in these reactions, by control-
ling the strand-specificity of binding to single-stranded (ss) ver-
sus double-stranded (ds) DNA substrates. BRCA2 binds direct-
ly to RAD51 through evolutionarily conserved BRC repeat mo-
tifs. In human BRCA2, 8 BRC motifs are dispersed in an 1127-
residue region encoded by exon 11, in which their spacing exhi-
bits conservation amongst mammalian species. We showed 
(Carreira et al., 2009; Shivji et al., 2009) that the binding of BRCA2 
BRC repeats to RAD51 suffices to promote the stability of 
RAD51-ssDNA binding, whilst inhibiting the binding of RAD51 
to dsDNA substrates. During strand exchange reactions, when 
Fig. 1. Structural chromosomal aberrations in metaphase
spreads from murine embryo fibroblasts homozygous for
a targeted truncation in Brca2. (A) shows a typical meta-
phase spread, with arrows marking abnormal chrom-
somes. Chromatid-type aberrations enlarged in (B-D)
show breaks affecting a single sister chromatid, tri-radial
and quadri-radial chromosomes respectively. Reproduced
with the permission of Elsevier from Patel et al. (1998). 
 
Fig. 2. Opposing effects of BRCA2 BRC repeats on RAD51
binding to ssDNA versus dsDNA bolster one another to
stimulate strand exchange. When BRCA2 BRC repeats
are absent (left-hand side), ssDNA and dsDNA compete
for RAD51 binding. Strand exchange is inefficient because
premature, stable RAD51 assembly on dsDNA is futile.
The BRC repeats of BRCA2 favour the preferential as-
sembly of RAD51 onto ssDNA because their interaction
with RAD51 promotes RAD51-ssDNA binding while sup-
pressing RAD51-dsDNA binding (right-hand side). These
opposing effects reinforce one another to guide stepwise
progression through strand exchange. Reproduced from
Shivji et al. (2009). 
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lates an unrecognized function for HMG20b in the efficient completion of cell division by cytokinesis. Thus, divergent tumour suppressive func-
tions maintaining chromosome segregation as well as chromosome structure may be mediated by the conserved BRC repeats of BRCA2. 
Reproduced from Lee et al. (2011). 
 
 
 
homologous ssDNA and dsDNA are both present, BRCA2 
stimulates strand exchange by preventing premature and ulti-
mately sterile engagement of RAD51 with dsDNA before forma-
tion of the ssDNA-RAD51 filament and the initiation of strand 
invasion and homologous pairing. Thus, BRCA2 targets RAD51 
to ssDNA while inhibiting dsDNA binding and these contrasting 
activities together bolster one another to stimulate HR (Fig. 2). 
Another role of BRCA2 whose loss may trigger chromosomal 
breakage is its essential function in the stabilization of stalled 
DNA replication forks in the late S and G2 phases of the cell 
cycle. Our laboratory showed several years ago that replication 
intermediates formed at stalled forks were broken down in 
BRCA2-deficient cells into dsDNA breaks (Lomonosov et al., 
2003), and this has been subsequently attributed to the inhibi-
tion of endonuclease activity at stalled forks in a manner that 
may be independent of RAD51-mediated DNA repair (Schla-
cher et al., 2011). 
Inactivation of BRCA2 also causes aneuploidy. Murine BRCA2- 
deficient cells accumulate with > 4N DNA content (Patel et al., 
1998), and aneuploidy is found in cancer cells from BRCA2 
mutation carriers. The origin of these anomalies is less clear, 
but may possibly be explained by functions of BRCA2 in mitotic 
progression at the spindle assembly checkpoint during the 
transition from metaphase to anaphase (Choi et al., 2012), 
and/or in the defective completion of cell division by cytokinesis 
at the stage of daughter cell abscission (Daniels et al., 2004; 
Lee et al., 2011; Mondal et al., 2012). However, roles for BRCA2 
in controlling mitotic entry following activation of the G2 check-
point for DNA damage have also been proposed (Ayoub et al., 
2009; Menzel et al., 2011), although it is currently unclear if 
their loss contributes to chromosomal instability in BRCA2-
deficient cells. 
Concerning the spindle assembly checkpoint, recent data 
suggest (Choi et al., 2012) that BRCA2 recruits the PCAF ace-
tyltransferase to the kinetochores of metaphase chromosomes 
during mitosis, facilitating the acetylation by PCAF of the kine-
tochore protein BubR1, increasing its stability. Inactivation of 
BRCA2 decreases BubR1 acetylation and the level of BubR1 
during mitosis, leading to weakened checkpoint activity and 
aneuploidy. 
BRCA2 inactivation also causes an increase in the frequency 
of cells that fail to complete division, but instead form multi-
nucleate structures with ≥ 4N DNA content (Daniels et al., 2004). 
Although cell cleavage by the actomyosin contractile ring can 
be initiated, and often reaches near-completion, in many divi-
sions the abscission of the daughter cells does not proceed 
further. Indeed, BRCA2 is localized to the cytokinetic midbody 
by filamin A, where it recruits components of the ESCRT (en-
dosomal sorting complex required for transport) protein com-
plex implicated in cytokinetic abscission (Mondal et al., 2012). 
Moreover, the cytokinetic role of BRCA2 appears to be separa-
ble (Lee et al., 2011) from its function in RAD51 regulation dur-
ing HR (Fig. 3). Thus, BRCA2 binds to the cytokinetic regulator 
HMG20b via the BRC repeat BRC5, which binds poorly to 
RAD51. Conversely, the BRC4 repeat binds strongly to RAD51, 
but not to HMG20b. In cells, BRC5 overexpression inhibits the 
BRCA2-HMG20b interaction, triggering defects in cytokinesis. 
In contrast, BRC4 inhibits the BRCA2-RAD51 interaction and 
the assembly of RAD51 at sites of DNA damage, but has no 
effect on cytokinesis. 
Thus, in summary, multiple functions for BRCA2 in the pre-
servation of chromosome stability may explain its tumour sup-
pressive function. These include functions in the control of 
RAD51 during DNA repair by homologous recombination, in 
mitotic entry at the G2/M transition, and in mitotic progression 
through functions at the spindle assembly checkpoint and dur-
ing cytokinesis. The loss of these functions may account for the 
observed aberrations in chromosome structure and number 
that occur when BRCA2 is inactivated in cancer cells. The oc-
currence of chromosomal instability, in turn, plausibly drives 
mutagenesis and neoplastic transformation in cells lacking 
BRCA2 (Venkitaraman, 2002; 2009). 
 
A GENETICALLY ENGINEERED MOUSE MODEL 
(GEMM) FOR TISSUE-SPECIFIC CARCINOGENESIS 
ASSOCIATED WITH BRCA2 DEFICIENCY 
 
Many genetically engineered mouse models (GEMMs) for the 
role of tumour suppressors in human carcinogenesis fail to 
recapitulate the complex combinations of germline and somatic 
alterations typically associated with human cancers, but instead, 
focus on the constitutive or conditional inactivation of one or 
both alleles of the tumour suppressor gene in different mouse 
tissues. In particular, human diseases associated with tumour 
suppressors such as BRCA2 involve germline BRCA2 altera-
tions in all somatic tissues, with loss of the second allele ex-
pected only in the developing cancer cells, where they coexist 
with a number of additional oncogenic or tumour suppressive 
alterations. The failure of most available GEMMs to mimic 
these features means that they are frequently of limited value in 
modeling human carcinogenesis or cancer therapy. 
To address this lacuna, we have created in our laboratory a 
GEMM for pancreatic cancer associated with inherited BRCA2 
mutations (Skoulidis et al., 2010). Pancreatic ductal adenocar-
Fig. 3. Divergent tumour-suppressive functions 
of the BRC repeats of BRCA2. The grey circle 
highlights in a schematic depiction of human 
BRCA2 the evolutionarily conserved region that 
contains 8 BRC repeats whose sequence and 
spacing is preserved amongst mammalian ortho-
logues. Most BRC repeats, including BRC4, are 
known to bind and control the RAD51 recombi-
nase in reactions that lead to homologous DNA 
recombination. BRC5 (but not BRC4) binds 
directly to HMG20b, and this interaction regu-
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cinoma (PDAC) represents the fourth leading cause of cancer 
mortality worldwide, with an incidence of approximately 217,000 
new cases each year associated with ~213,000 deaths (Parkin 
et al., 2001). The most frequent genetic events underlying the 
initiation and progression of human pancreatic cancer (Hezel et 
al., 2006; Maitra and Hruban, 2008) include activating muta-
tions in the KRAS proto-oncogene, in > 90% of PDAC cases 
(Caldas and Kern, 1995), besides mutations inactivating the 
TP53 gene in 50-75% of patients (Redston et al., 1994). More-
over, mutations inactivating BRCA2 are found in an estimated 
5-20% of familial PDAC (Couch et al., 2007; Hahn et al., 2003). 
Conversely, germline inheritance of pathogenic BRCA2 muta-
tions carries an ~4-8-fold increased lifetime risk of developing 
PDAC (Breast Cancer Linkage Consortium, 1999).  
In patients with germline mutations in BRCA2, all somatic tis-
sues contain the mutant allele, whereas the second BRCA2 
allele is wildtype (Wooster et al., 1994). Loss of this second, 
wild-type BRCA2 allele in nascent cancer cells (termed ‘loss of 
heterozygosity’ or LOH) is widely believed to be essential for 
carcinogenesis in these patients. The pancreatic cancer model 
developed in our laboratory (Skoulidis et al., 2010) recapitulates 
these events (Fig. 4). A truncated allele of murine Brca2 (Brca2Tr), 
resembling deleterious human germline mutations, which trun-
cates the gene in an evolutionarily conserved and functionally 
critical region encoded by exon 11, is present in all somatic 
tissues (Friedman et al., 1998). The second Brca2 allele, Brca2F11 
(Jonkers et al., 2001) can be conditionally disrupted to remove 
exon 11 by loxP-CRE recombination in the pancreas when 
PDX1-CRE is expressed there, mimicking LOH in human can-
cers from mutation carriers. Notably, tissue-specific activation of 
oncogenic KrasG12D is driven on a single allele by loxP-CRE 
mediated recombination in the pancreas, mimicking a genetic 
event that frequently triggers Kras activation in human cancers. 
In addition, in some strains, the mutant p53 allele mutant 
Tp53R270H can also be activated in the pancreas via CRE-
mediated recombination. Thus, this mouse model not only faith-
fully recapitulates several of the key genetic alterations that 
have been implicated in PDAC pathogenesis, but also mimics 
the combination of mutant BRCA2 alleles found in the somatic 
tissues and cancer tissues from BRCA2 mutation carriers.  
Unexpectedly, our studies reveal that BRCA2 heterozygosity 
is sufficient to promote pancreatic cancer development in mice 
and men; inactivation of the second wild-type allele by LOH is 
not necessary. Irrespective of p53 mutations, heterozygosity for 
Brca2Tr acts with KrasG12D to accelerate the progression and 
development of PDAC. Similarly, in a small number of human 
pancreatic cancer samples from carriers of the Icelandic found-
er mutation in BRCA2 (BRCA2999Del5) (Mikaelsdottir et al., 2004), 
the majority (75%) of the cases tested do not exhibit LOH. 
These findings suggest that BRCA2 - contrary to belief - does 
not act as a typical Knudson ‘two hit’ tumour suppressor. 
It is not clear how heterozygosity for Brca2Tr can promote 
tumourigenesis. One possibility is that this genotype causes 
defects in DNA repair, but this is not convincingly borne out by 
studies on cells derived from Brca2Tr-heterozygous mice (Patel 
et al., 1998; Yu et al., 2000), or from a similar transgenic model 
carrying another truncating allele in Brca2 (Tutt et al., 2002). 
Thus, the evidence that heterozygosity for the Brca2Tr mutant 
allele creates a DNA repair defect is not convincing, although 
the possibility has not yet been fully excluded. 
Our laboratory has recently identified (Jeyasekharan et al., 
2013) a protein-targeting mechanism that is disrupted even by 
heterozygosity for the human mutation BRCA2D2723H, which is 
associated with cancer. We find that in the mutant protein 
BRCA2D2723H a nuclear export signal in BRCA2 that is normally 
masked by its interaction with a partner protein, DSS1, is ex-
posed, rendering the mutant BRCA2D2723H into a substrate for 
binding by the nuclear exportin CRM1. This mislocalizes mutant 
BRCA2D2723H into the cytoplasm, in turn decreasing RAD51 
nuclear retention even when wild-type BRCA2 is also present. 
Thus, these findings suggest that a mechanism regulating the 
normal nucleo-cytoplasmic distribution of BRCA2 and RAD51 
can be impaired by a heterozygous cancer-associated mutation.  
 
BRCA2 HETEROZYGOSITY SUFFICES FOR 
CARCINOGENESIS: IMPLICATIONS FOR CANCER 
THERAPY 
 
Our results suggesting that Brca2 heterozygosity is sufficient for 
pancreatic carcinogenesis driven by mutant Kras in mice and 
men have important implications for cancer therapy. This is 
because the rationale for the use of targeted agents such as 
PARP1 inhibitors (PARP1i) in BRCA2-deficient cancers re-
quires bi-allelic BRCA2 inactivation in the tumour cells (Bryant 
et al., 2005; Farmer et al., 2005). Indeed, we have shown in our 
work (Skoulidis et al., 2010) that PDAC cells that retain a func-
tional Brca2 allele are resistant to PARPi such as the AstraZe-
neca compound Olaparib. Our findings argue that in humans, 
PARP1 inhibitors should only be used in patients when BRCA2 
LOH can be verified in the tumour. Assessment of LOH there-
fore becomes a critical requirement in the design of human 
clinical trials for the treatment of BRCA2-deficient cancers. 
There is mounting evidence that heterozygosity for BRCA2 is 
sufficient for human carcinogenesis in tissues other than the 
pancreas, with the attendant implications for therapy using 
PARP1i. Lack of LOH has been documented using different 
methods in up to ~30% of breast cancers (King et al., 2007), by 
NGS in ~25% high-grade serous ovarian carcinomas (Cancer 
Genome Atlas, 2011), and in up to 55% of prostatic cancers 
associated with BRCA2 mutation carriers (Willems-Jones et al., 
2012). Thus, it will be essential in future clinical trial designs to 
test for LOH in tumour samples to help stratify likely responders 
to PARP1i or similar targeted therapies. 
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